Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Director's Dealing 2016

Sep 15, 2016

4797_dirs_2016-09-15_c3bfdcab-efa3-4e18-85c1-3555f5da6f0b.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9802J

Dechra Pharmaceuticals PLC

15 September 2016

15 September 2016

Dechra Pharmaceuticals PLC

(the Company)

Director Shareholding

The Company announces that on 14 September 2016 the following Directors were granted awards over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the Plan):

Name of individual Director Type of award Number of shares subject to award
Ian Page Director LTIP Award - nil cost option 73,667
Tony Griffin Director LTIP Award - Conditional award 20,858

The vesting of all the above awards is subject to the achievement of performance targets.  In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period.  Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance measure.  If the ROCE performance condition is not met, then the LTIP options will lapse in full.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
2. Reason for the notification
a) Position/status Director
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Grant of nil cost options under the Company's Long Term Incentive Plan
c) Price(s) and volumes(s) Price(s)

Nil cost
Volume(s)

73,637
d) Aggregated information

-   Aggregate volume

-   Price
N/A
e) Date of the transaction 2016.09.14
f) Place of the transaction Outside a trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
2. Reason for the notification
a) Position/status Director
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB009633180
b) Nature of the transaction Grant of a conditional award under the Company's Long Term Incentive Plan
c) Price(s) and volumes(s) Price(s)

Nil cost
Volume(s)

20,858
d) Aggregated information

-   Aggregate volume

-   Price
N/A
e) Date of the transaction 2016.09.14
f) Place of the transaction Outside a trading venue

For further information, please contact:

Suzana Cross, Company Secretary           

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHAKPDBQBKDFCD